Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
RDHL Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: September 19, 2025
Report Source: 2025 2nd Quarter Report
Redhill Biopharma Ltd. Stock Analysis RDHL
United States Health Care Nano Cap Report: RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.
Read More Redhill Biopharma Ltd (RDHL) Chart
Key Statistics of Redhill Biopharma Ltd (RDHL)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$0.90Volume
126.48KP/E Ratio (TTM)
-52 Week Range
Market Cap
4.77MAvg. Volume
497.91KDividend Yield
-Financial Metrics & Statements of Redhill Biopharma Ltd (RDHL)
FAQ's for Redhill Biopharma Ltd (RDHL)
- According to Musaffa’s Shariah screening methodology, Redhill Biopharma Ltd (RDHL) is currently classified as NOT HALAL as of September 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Redhill Biopharma Ltd using these criteria to determine its compliance status.
- Muslim investors may consider investing in Redhill Biopharma Ltd if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Redhill Biopharma Ltd by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Redhill Biopharma Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Redhill Biopharma Ltd on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.